Switching between raltegravir resistance pathways analyzed by deep sequencing Rithun Mukherjeea, Shane T. Jensenb, Frances Malea, Kyle Bittingera, Richard L. Hodinkac,d, Michael D. Millere and Frederic D. Bushmana Object

Source URL: www-stat.wharton.upenn.edu

12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

Source URL: www.nzma.org.nz

• Clinical medicine
• Breakthrough therapy
• Medicine
• Antineoplastic drugs
• Pharmacology
• Monoclonal antibodies
• Bristol-Myers Squibb
• Nivolumab
• Melanoma
• Programmed cell death protein 1
• Pembrolizumab
• Raltegravir

Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (avrilANRS 160 RalFE Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir pendant l

Source URL: www.anrs.fr

ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL

Source URL: www.medicinespatentpool.org

• Cyclopropanes
• Non-nucleoside reverse transcriptase inhibitors
• Antiretroviral drug
• Abacavir
• Reverse-transcriptase inhibitor
• Nevirapine
• Efavirenz
• Patent
• Raltegravir
• Chemistry
• Organic chemistry
• Organofluorides

Merck Sharp Dohme Haarlem raltegravir Isentress HIV aanbiedingsbrief rapporten ministerPOVOOPEN.DOC

Source URL: www.zorginstituutnederland.nl

Instructions for Use ISENTRESS® (eye sen tris) (raltegravir) for oral suspension Read this Instructions for Use before you mix and give a dose of ISENTRESS for oral suspension to your child for the first time, and each

Source URL: www.merck.com

• Chemistry
• Medicine
• Syringe
• Merck & Co.
• Raltegravir
• Dose
• Dosing
• Pharmacology
• Medical equipment
• Drug paraphernalia

  Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Health
• HIV/AIDS
• Amides
• Oxadiazoles
• Raltegravir
• Lamivudine
• GlaxoSmithKline
• Dolutegravir
• Organofluorides
• Chemistry
• Integrase inhibitors

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Medicine
• Amides
• Merck
• Oxadiazoles
• Raltegravir
• Integrase
• Dolutegravir
• ViiV Healthcare
• Integrase inhibitors
• Chemistry
• Organofluorides

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)

Source URL: shionogi616.tew-staging.com

• Health
• Medicine
• Integrase inhibitors
• GlaxoSmithKline
• ViiV Healthcare
• Lamivudine
• Pfizer
• Integrase
• Raltegravir
• Organofluorides
• Chemistry
• HIV/AIDS

ISENTRESS ™(raltegravir), in Combination with tenofovir /lamivudine, Showed Durable and Potent Antiretroviral Activity in Treatment Naïve, HIV-1 Infected Patients, with Similar HIV RNA Reduction to Efavirenz in Combin

Source URL: www.msd-italia.it